Bio-Rad Laboratories and Axis-Shield have signed an agreement that gives Bio-Rad access to Axis-Shield's test for the early detection of rheumatoid arthritis
The assay, which will run on Bio-Rad's BioPlex 2200 system, tests for anti-CCP (anti-cyclic citrullinated peptide antibodies).
The anti-CCP assay is a significant recent development in the early diagnosis of rheumatoid arthritis, facilitating improved management of this widespread and debilitating condition.
"The ability to incorporate an anti-CCP test as part of a rheumatoid arthritis panel will add significantly to our growing menu of autoimmune tests on the BioPlex 2200 system," said John Goetz, Bio-Rad vice president and group manager of clinical diagnostics.
"As the first and only fully automated, random access multiplex testing platform, the BioPlex 2200 system is ideally suited as a platform for multi-marker autoimmune testing that includes rheumatoid arthritis".
"We are very pleased that our important patented assay for anti-CCP will be added to the menu of this versatile platform," said Svein Lien, Axis-Shield CEO.
"We have a history of successful collaboration with Bio-Rad, which is a highly respected and pioneering organisation in life sciences and a major player in human diagnostic testing and believe the BioPlex 2200 system will add an extra dimension to anti-CCP marketing".
The BioPlex 2200 system is a fully automated, random access multiplex testing platform that can deliver up to 2200 results per hour.
The system currently includes a panel of assays targeting autoimmune diagnostics.
